Skip to content

Breast Cancer

EU Focus Meeting 2026


📍 SANA Malhoa Hotel, Av. José Malhoa 8, 1099-089 Lisbon, Portugal

🗓️ September 25 - 26, 2026


Last Year's Highlights

uems-eaccme-logo

CME Accreditation

The Breast Cancer Focus Meeting 2026, Lisbon, Portugal 25/09/2026 - 26/09/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn. org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Breast Cancer Focus Meeting 2026, to be held on September 25 - 26, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Breast Cancer research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of Breast Cancer EU Focus Meeting 2026:

Javier-Cortes

Javier Cortés
International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain

Virginia-Kaklamani

Virginia Kaklamani
UT Health, San Antonio, TX

Thanks to Our Supporters

Agenda & Faculty

Friday, 25 September, 2026 | Day 1  

10:00
Registration Opens

Session I: Updates in HER2 Positive Breast Cancer
Moderated by:

Javier-Cortes
Javier Cortés
International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
11:05
How to Optimize Regimens in the Adjuvant Setting
Luis_Marques da Costa_photo
Luis Marques da Costa          Hospital de Santa Maria, Lisbon, Portugal
11:25
Treatment Landscape in Metastatic HER2 Positive Breast Cancer
Javier-Cortes
Javier Cortés                       International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
11:45
Novel Anti HER2 Agents
Giampaolo-Bianchini
Giampaolo Bianchini
San Raffaele Scientific Institute, Milan, Italy
12:05
12:25
12:55
Panel Discussion
Coffee Break
Symposium supported by F. Hoffmann-La Roche Ltd

Session II: Risk Reduction, Early Detection and Local Therapy
Moderated by:

Virginia-Kaklamani
Virginia Kaklamani                                                                                                                                                                                                   
UT Health, San Antonio, TX
13:40 
Can we Omit SLN Altogether?
Isabel-T-Rubio
Isabel T. Rubio
Clínica Universidad de Navarra, Spain
14:00
What’s New on Chemoprevention?
Andrea-De-Censi
Andrea De Censi
Champalimaud Foundation, Lisbon, Portugal
14:20
14:40
Panel Discussion
Lunch Break + Faculty and Fellow Photo

Session III: HR+ Early Stage Breast Cancer
Moderated by:

Virginia-Kaklamani
Virginia Kaklamani
UT Health, San Antonio, TX
15:40
Who Needs OFS?
Alessandra Gennari
Alessandra Gennari               University of Eastern Piedmont, Italy

16:00
Use of Genomic Tools to Help with Chemotherapy Decisions
Antonio-Llombart-Cussac
Antonio Llombart-Cussac                  University Hospital Arnau de Vilanova, Valencia, Spain
16:20
Optimizing Endocrine Therapy in Early Stage Breast Cancer
François-Clément Bidard
François-Clément Bidard
Institut Curie, Paris, France
16:40
17:00
Panel Discussion
Adjourn

Saturday, 26 September, 2026 | Day 2  

08:30
Registration and Coffee Break

Session IV: Triple Negative Breast Cancer
Moderated by:

Virginia-Kaklamani
Virginia Kaklamani                                                                                                                                                                                                       UT Health, San Antonio, TX
09:05
The Future of ADCs: New Payloads, New Targets
Hope-Rugo
Hope Rugo
City of Hope, Duarte, CA
09:25
How to Address High Risk TNBC
Ana-GarridoCastro
Ana Garrido-Castro
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
09:45
MRD: Should We Use it in Clinic?
Emmanouil Saloustros
Emmanouil Saloustros
University of Thessaly, Volos, Greece
10:05
How Can We Define Low Risk TNBC
Marleen Kok
Marleen Kok
Netherlands Cancer Institute, Amsterdam, Netherlands
10:25 
10:45 
Panel Discussion
Coffee Break

Session V: Breast Cancer: Difficult to Treat Situations
Moderated by:

Javier-Cortes
Javier Cortés                                                                                                                                                                                                   International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
11:05
CNS Metastases
Rupert-Bartsch
Rupert Bartsch
Medical University of Vienna, Austria
11:25
Oligometastatic Breast Cancer
Antonio-Llombart-Cussac
Antonio Llombart-Cussac                 University Hospital Arnau de Vilanova, Valencia, Spain
11:45
Postmastectomy Radiation
Philip-Poortmans
Philip Poortmans
University of Antwerp, Belgium
12:05
12:25
13:15
Panel Discussion
Lunch Break
Independent Expert Discussion Supported by Lilly

Session VI: HR+ Metastatic Breast Cancer
Moderated by:

Virginia-Kaklamani
Virginia Kaklamani
UT Health, San Antonio, TX

 

14:00
What is the Optimal First-line Strategy?
DIOGO MARTINS-BRANCO_XS-2
Diogo Martins-Branco 
University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
14:20
How to Treat MBC Beyond CDK 4/6 Inhibitors
Virginia-Kaklamani
Virginia Kaklamani                          UT Health, San Antonio, TX
14:40
The Future of ADCs in HR+ MBC
Nicla-La_Verde
Nicla La Verde
ASST Fatebenefratelli Sacco – Luigi Sacco University Hospital, Milan, Italy
15:00
15:20
Panel Discussion
Coffee Break

Session VII: ADCs in MBC & Risk-Reducing Strategies: Optimizing the Right Approach
Moderated by:

Javier-Cortes
Javier Cortés
International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
15:40
Mechanisms of Resistance to ADCs
Barbara-Pistilli
Barbara Pistilli
Gustave Roussy Institute, Villejuif, France
16:00
Sequencing ADCs in Clinical Practice
Carlos-Barrios
Carlos H. Barrios
Hospital São Lucas of PUCRS, Porto Alegre, Brazil
16:20
Optimal Risk-reducing Management for BRCA1/2 Carriers
Matteo-Lambertini
Matteo Lambertini
Ente Ospedaliero Ospedali Galliera, Genoa, Italy
16:40
17:00
Panel Discussion
Adjourn

Cristina Anton
Lead Project Manager

How long has Cristina Anton been in the business?

Cristina Anton has been with MD Education since 2022.

About Cristina Anton

As a Lead Project Manager at MD Education’s Wigan office since 2022, I organize international medical conferences with a focus on breast cancer and inflammatory bowel disease (IBD). Originally from Romania, I have been based in the UK since 2015. My diverse background across sectors helps me deliver high-quality, impactful educational programs. I’m committed to excellence and continuous growth.

Cristina-Anton